AuthorisedHuman Pharmacology (Phase I)- OtherInterventional

Safety of stem cells in treatmemt of retinal diseases.

This research study is about checking the safety of using something called 'stem cells' to help people with eye problems that affect their retina. The retina is a special light-sensing part at the back of your eye that helps you see. When it gets damaged, it can lead to serious sight problems. This is an early and small study, often called a Phase I trial. Its main goal is to carefully watch for any side effects or problems when stem cells are used. It's not yet trying to see if the treatment works, but rather if it's safe enough to study further. People aged 18 and over, both men and women, can potentially take part.

At a glance

Status

Authorised

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Bioinova a.s.

Enrolment target

Start

28 Apr 2026

Retinal degenerative diseases

What is this study about?

This study is about a new way to treat eye diseases that affect your retina. Your retina is at the back of your eye and works like the film in a camera, sensing light and sending messages to your brain so you can see. When the retina gets damaged, it can cause vision loss. The scientists in this study are looking at using 'stem cells' as a possible treatment.

Stem cells are special cells that have the ability to change into different types of cells in the body. The idea is that these stem cells might be able to help repair or protect the damaged parts of the retina. This is a very early stage of research, often called Phase I. Think of it like a first test drive for a new car – the main thing they're checking is if it's safe to be on the road, not yet how fast it can go or how fuel-efficient it is.

So, the main goal of this particular study is to carefully monitor people who receive stem cell treatment for their retinal disease. They want to see if there are any unexpected side effects or problems, and to understand how the body reacts to the stem cells. If it proves to be safe, then larger studies in the future will explore whether this treatment can actually improve vision or stop the disease from getting worse.

Key takeaways

This is an early study looking at the safety of stem cells for retinal diseases.
It's not yet trying to prove if the treatment works, but if it's safe to use.
Adults aged 18 and over, with retinal conditions, can potentially take part.
Participation involves screening, treatment, and regular follow-up visits.
You can withdraw from the study at any time without affecting your care.

Who may be eligible?

To be considered for this study, you need to be an adult, aged 18 years or older. There is no upper age limit, meaning older adults can also take part. The study is open to everyone, whether you are male or female.

The most important requirement is that you have a type of eye problem that affects your retina. The doctors running the study will carefully check your specific eye condition to see if it matches what they are looking for. They'll also check your overall health to make sure it's safe for you to participate.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a medical condition affecting your retina (the back of your eye)?
Are you able to attend regular clinic appointments for follow-up?
Are you comfortable with receiving an experimental treatment?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would first have a number of screening visits. During these visits, doctors would do various tests and examinations to check your eye condition and overall health, to make sure this study is right for you. Once you are accepted, you would receive the stem cell treatment.

After the treatment, you would need to attend regular follow-up visits to the clinic. These visits are very important as they allow the study team to carefully monitor your eyes and your general health, looking for any changes or side effects. This could involve eye examinations, blood tests, and scans. The total time you would be involved in the study would depend on how long they need to monitor safety, but these types of early studies usually involve follow-up over several months to a year or more.

Potential risks and benefits

Taking part in any medical study has potential benefits and potential risks. For this early safety study, the potential direct benefit to your vision is not known, as the main aim is to check for safety. However, by taking part, you would be helping doctors learn more about diseases affecting the retina and potentially helping future patients. Possible risks include side effects from the stem cell treatment itself, such as infection, inflammation, or unexpected reactions to the cells. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Czechia

Common questions

What are stem cells?

Stem cells are special cells in your body that can develop into different types of cells, like eye cells or skin cells, and can also repair damaged tissue.

What is the retina?

The retina is the light-sensitive layer at the back of your eye that works like a camera film, helping you see by sending images to your brain.

Will this treatment cure my eye condition?

This early study is mainly focused on safety, not on whether the treatment will cure or improve your vision. That will be looked at in later studies.

Who can take part in this study?

Adults aged 18 and over, both men and women, who have a retinal disease may be able to join. Your doctor will check if you meet all the criteria.

How long will I be involved in the study?

The length of your involvement will depend on the study plan, but early safety studies usually involve regular check-ups over several months to over a year.